title: Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients.
abstract: BACKGROUND
  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) down-regulation by preferentially expressed antigen of melanoma (PRAME) is a general phenomenon in different types of solid tumours, but research on the correlation between PRAME and TRAIL gene expression in leukaemia patients is rare.
  
  
  METHODS
  PRAME and TRAIL expression was detected in bone marrow samples from 80 newly diagnosed acute leukaemia (AL) patients and 40 chronic myeloid leukaemia (CML) patients using TaqMan-based real-time quantitative PCR methods, and a linear correlation analysis was performed on their levels of expression. A total of 15 normal bone marrow samples from individuals with non-malignant haematological diseases served as normal controls.
  
  
  RESULTS
  PRAME expression was higher in both AL and CML patients compared to controls (both p < 0.001). CML patients in both blast crisis (BC) and the accelerated phase (AP) had significantly higher PRAME levels than CML patients in the chronic phase (CP) (p = 0.006 and 0.0461, respectively). TRAIL expression was higher in both the acute myeloid leukaemia (AML) group and the acute lymphoblastic leukaemia (ALL) group than in the controls (p = 0.039 and 0.047, respectively). In contrast, CML patients had lower TRAIL levels than controls (p = 0.043), and TRAIL expression in CML patients in the advanced phases (BC and AP) was significantly lower than in CML-CP patients (p = 0.006). In CML patients, there was a significant inverse correlation (Spearman's R = -0.6669, p < 0.0001) between PRAME and TRAIL gene expression, while a greater significant inverse correlation was found in patients in the advanced phases (BC and AP) (R = -0.6764). In addition, no correlation was observed in AML and ALL patients.
  
  
  CONCLUSIONS
  The simultaneous detection of PRAME and TRAIL gene expression may be helpful to monitor condition changes in leukaemia patients and evaluate therapeutic effects in clinical practice, particularly in CML patients.
authors.affiliation: Department of Hematology, Henan Provincial Hospital, Zhengzhou University, Zhengzhou, PR China.
authors.forename: Wenhui
authors.initials: W
authors.lastname: Zhang
authors.forename: Kaikai
authors.initials: K
authors.lastname: Chi
authors.forename: Yin
authors.initials: Y
authors.lastname: Zhang
authors.forename: Baogen
authors.initials: B
authors.lastname: Ma
authors.forename: Jie
authors.initials: J
authors.lastname: Shi
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Chen
authors.forename: Pingchong
authors.initials: P
authors.lastname: Lei
authors.forename: Yulong
authors.initials: Y
authors.lastname: Li
authors.forename: Kai
authors.initials: K
authors.lastname: Sun
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics*; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000235:genetics* / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000276:immunology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics*
chemical_list: D000951:Antigens, Neoplasm; C404944:PRAME protein, human; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human